It used to be – “buy now, buy now”, plain and simple, but these days Nuvilex Inc(PINK:NVLX) enjoys a different type of promotion. It was third parties that used to pay for paid newsletters; thus companies would not mention them on their web pages. Again, not the case for Nuvilex. 
While most people have probably heard of Goldman Sachs, a few are familiar with Goldman Small Cap Research. As the name suggests, this is a company preparing reports for publicly trading enterprises just like Nuvilex. This week, day after day, updates are coming from Goldman, all focusing on the potential of Nuvilex. The result as with most promotions – trading volumes skyrocket, the price however, fails to do so. More than 16 million shares exchanging hands on Wednesday, less than 8 million on Thursday, the latter session closing at $0.06 per share. [BANNER]
Actually, this promotional campaign started in the beginning of May. The difference is that back then there was real price movement on the stock market – from $0.026 to $0.07 per share in a matter of days. Well, there was a target for the money paid to Goldman. The interesting part comes when browsing through the Nuvilex Website. All research updates from Goldman are in there, in the news section. As if Nuvilex wants people to know the company is promoted heavily by Goldman. After all, it is not difficult to read the disclaimer in all the reports coming out every now and then. Read about the compensation, about the fact that all information used in the report is provided by Nuvilex, not by independent sources.
The above, in terms, brings nothing but uncertainty as to how the stock would perform in the weeks and months to come. There were real positive announcements recently as well, such as the one about the acquisition of the pancreatic cancer treatment technology. Whether positive announcements would transform into optimistic-looking balance sheets is another matter entirely.
